CD44 and bone neoplasm: It is also known that HA-CD44 interactions activate a variety of signaling pathways (including the PI3K pathway) that contribute to stimulation of ABCB1 expression, leading to drug resistance in breast and ovarian tumor cells [43] and bone tumor cells [44].